NEW YORK--(BUSINESS WIRE)--ZIOPHARM Oncology, Inc. (NASDAQ: ZIOP) announced that it is hosting its first Investor/Analyst Day today at the Yale Club in New York City, beginning at 8:00 a.m. ET featuring presentations from ZIOPHARM management and key opinion leaders in the field of clinical oncology. Among other things, the Company expects to discuss upcoming milestones related to its current portfolio of three clinical stage cancer therapeutics – ZIO-101 (proprietary organic arsenic), ZIO-201 (proprietary IPM) and ZIO-301 (indibulin).
